ABVC Biopharma Inc.
09/12/2025 | Press release | Distributed by Public on 09/12/2025 04:02
Amendment to Current Report (Form 8-K/A)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 12, 2025 (October 18, 2024)
ABVC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 001-40700 | 26-0014658 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
44370 Old Warm Springs Blvd. Fremont, CA |
94538 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number including area code: (510) 668-0881
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of each exchange on which registered | ||
| Common Stock, par value $0.001 per share | ABVC | TheNasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 4.01 Changes in Registrant's Certifying Accountant.
We filed a Current Report on Form 8-K on October 18, 2024, to disclose that on October 10, 2024, WWC, P.C. ("WWC"), serving as the Company's independent registered public accounting firm, agreed not to renew its engagement with the Company (the "Original 8K").
As disclosed in the Original 8K, although we provided WWC with a copy of the Original 8K and requested WWCto furnish us with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made therein, WWC had not yet agreed or declined to provide such a letter. As of the date hereof, WWC has refused to provide us with such a letter.
1
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABVC BioPharma, Inc. | ||
| September 12, 2025 | By: | /s/ Uttam Patil |
| Uttam Patil | ||
| Chief Executive Officer | ||
2
ABVC Biopharma Inc. published this content on September 12, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 12, 2025 at 10:03 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]